Cue Biopharma (CUE) EBITDA Margin (2018 - 2025)
Cue Biopharma (CUE) posted EBITDA Margin of 20.82% for Q4 2025, up 105.89% sequentially from 353.42% in Q3 2025, and up 63205.0% YoY from N/an in Q4 2024.
Cue Biopharma (CUE) EBITDA Margin (2018 - 2025) Analysis & Trends
Cue Biopharma has reported EBITDA Margin for 8 years, with the latest figure at 20.82% in Q4 2025.
- Quarterly EBITDA Margin rose 63205.0% year-over-year to 20.82% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 176.72% (up 27013.0% YoY) and the FY2025 annual result came in at 96.67%, up 35019.0% from the prior year.
- EBITDA Margin rose to 20.82% in Q4 2025 per CUE's latest filing, from 353.42% in the prior quarter.
- Over five years, EBITDA Margin peaked at 20.82% in Q4 2025 and troughed at 50346.15% in Q2 2022.
- A 5-year average of 4732.26% and a median of 674.51% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin plunged 4996999 bps in 2022, then jumped 4936808 bps in 2023.
- Over 5 years, EBITDA Margin stood at 95.62% in 2021, then slumped by 10196 bps to 9845.03% in 2022, then surged by 92 bps to 759.58% in 2023, then grew by 20 bps to 611.23% in 2024, then surged by 103 bps to 20.82% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 20.82%, 353.42%, and 292.32% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | -1,113.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20.82% |
| Sep 30, 2025 | -353.42% |
| Jun 30, 2025 | -292.32% |
| Mar 31, 2025 | -2,921.38% |
| Dec 31, 2024 | -611.23% |
| Sep 30, 2024 | -264.24% |
| Jun 30, 2024 | -390.63% |
| Mar 31, 2024 | -737.80% |
| Dec 31, 2023 | -759.58% |
| Sep 30, 2023 | -543.76% |
| Jun 30, 2023 | -978.08% |
| Mar 31, 2023 | -7,155.08% |
| Dec 31, 2022 | -9,845.03% |
| Sep 30, 2022 | -16,222.06% |
| Jun 30, 2022 | -50,346.15% |
| Mar 31, 2022 | -1,423.80% |
| Dec 31, 2021 | -95.62% |
| Sep 30, 2021 | -543.55% |
| Jun 30, 2021 | -376.16% |
| Mar 31, 2021 | -806.05% |